MAM
KRYS icon

Meeder Asset Management’s Krystal Biotech KRYS Stock Holding History

Meeder Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26
Closed -$4.07K – 978
2024
Q4 		$4.07K Buy
+26
New +$4.61K ﹤0.01% 854
2020
Q3 		– Sell
-501
Closed -$21K – 2280
2020
Q2 		$21K Hold
501
– – ﹤0.01% 1118
2020
Q1 		$21K Sell
501
-1,167
-70% -$61K ﹤0.01% 1226
2019
Q4 		$93K Buy
1,668
+1,421
+575% +$69.7K 0.01% 807
2019
Q3 		$8K Buy
+247
New +$11K ﹤0.01% 1605

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Meeder Asset Management's KRYS Position: Q1 2025 in Review

Meeder Asset Management sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 26 shares — an estimated $4.07K sold.

Meeder Asset Management first reported a position in KRYS in Q3 2019 and held it in 5 quarters. The position peaked at $93K in Q4 2019. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Meeder Asset Management reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Meeder Asset Management sold 26 Krystal Biotech shares in Q1 2025, an estimated $4.07K.
  • Meeder Asset Management first reported a position in Krystal Biotech in Q3 2019 and held it in 5 quarters.
  • Meeder Asset Management's Krystal Biotech position peaked at $93K in Q4 2019.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Meeder Asset Management's 13F filing for Q1 2025, filed 7 May 2025.